Matthias W Beckmann
Matthias W Beckmann is an expert in Oncology at Universitätsklinikum Erlangen (Germany). As of October 2026, ScienceLeadR ranks Matthias W Beckmann in the top 1% of experts worldwide for Breast Diseases, Breast Neoplasms and Adnexal Diseases. Matthias W Beckmann has authored 1,321 publications, the most recent in 2026, and is an investigator in 9 clinical trials. SLR score: 3,413 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Gynecology - Obstetrics - Genetics
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1991 - 2026
Number : 1321
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Beyond a single ratio: an adaptable deep learning approach to analyze the prognostic value of TSP distribution in ovarian cancer. PMID 42947509 — telepathology, ovary, neoplasms, pathology, biomarkers, deep learning, ovarian neoplasms, learning | J Pathol | 2026 | 0 |
| Nectin-4 expression in vulvar squamous cell carcinoma. PMID 41888429 — cells, carcinoma, squamous cell, nectins, pathology, lymph, therapeutics, tissues | Virchows Arch | 2026 | 0 |
| Consequences of Maternal Antidepressant and Anticonvulsant Use During Pregnancy: Is Postnatal Inpatient Monitoring Required? - A Retrospective Cohort Study. PMID 42846632 — antidepressive agents, pregnancy, infant, newborn, maternal age, cohort studies, gestational age, anticonvulsants | Geburtshilfe Frauenheilkd | 2026 | 0 |
| Risk-reducing salpingo-oophorectomy in patients with gBRCA-mutated breast cancer. PMID 42804048 — breast neoplasms, probability, neoplasms, obstetrics, breast, gynecology, diagnosis, salpingo-oophorectomy, mutation, ovariectomy | Arch Gynecol Obstet | 2026 | 0 |
| Clinical Relevance of Post-Treatment Circulating Tumor DNA Detection in Early Breast Cancer Using a Tissue-Free Epigenomic Assay: A 2-Year Landmark Analysis. PMID 42696691 — circulating tumor dna, breast neoplasms, epigenomics, neoplasms, drug therapy, chemotherapy, adjuvant, breast, precision medicine, therapeutics, tissues, chemotherapy | JCO Precis Oncol | 2026 | 0 |
Clinical Studies 9
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 1
LeadR Networks
Main global connection map